Latin America Cancer Biopsy Market Overview:
The Latin America Cancer Biopsy Market size was valued at USD 6,236.16 MN in 2021 and reached USD 9,108.79 MN in 2025. It is anticipated to reach USD 18,855.52 MN by 2032, growing at a CAGR of 9.20% during the forecast period.
| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2021-2024 |
| Base Year |
2025 |
| Forecast Period |
2025-2032 |
| Latin America Cancer Biopsy Market Size 2025 |
USD 9,108.79 million |
| Latin America Cancer Biopsy Market, CAGR |
9.20% |
| Latin America Cancer Biopsy Market Size 2032 |
USD 18,855.52 million |
Latin America Cancer Biopsy Market Insights
- Market growth is supported by rising cancer diagnosis volumes, wider access to pathology services, adoption of liquid biopsy, growth in molecular testing and stronger demand for precision oncology.
- Consumables hold a strong position because biopsy procedures require recurring use of needles, specimen containers, reagents, slides, preservation media and sample preparation materials.
- Tissue Biopsies remain the leading type because they are widely used for histopathology confirmation, tumor grading, receptor testing and treatment planning across major cancer indications.
- Hospitals remain the leading end user because complex biopsy procedures, pathology workflows, imaging guidance and oncology treatment pathways are concentrated in hospital-based care networks.
Latin America Cancer Biopsy Market Segment Insights
By product
By product, Consumables held a strong position in 2025 because cancer biopsy testing depends on recurring use of specimen collection, preparation, preservation and analysis materials. Hospitals and Diagnostic Centres require consistent supplies of biopsy needles, sample containers, reagents, slides, stains, cartridges and molecular testing consumables. Kits are gaining traction as laboratories adopt standardized workflows for tissue and liquid biopsy testing. Instrument demand is supported by imaging-guided biopsy systems, automated sample processors, sequencing platforms, pathology systems and liquid biopsy analysis tools. Services remain important because laboratories and hospitals depend on outsourced testing, molecular profiling, pathology interpretation and technical support. The market will favor suppliers that offer integrated products, reliable supply and training support.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Download Sample
By type
By type, Tissue Biopsies led the Latin America Cancer Biopsy Market in 2025 because they remain the primary diagnostic method for confirming tumor presence, histology, grade and biomarker status. Tissue testing is widely used across lung cancer, breast cancer, colorectal cancer, prostate cancer and other cancers. Liquid Biopsies are expected to gain strong momentum because they support minimally invasive testing, genomic profiling, therapy selection and disease monitoring where tissue collection is difficult or insufficient. Liquid biopsy adoption is still shaped by affordability, reimbursement, laboratory readiness and physician awareness. Both biopsy types will remain complementary because tissue testing supports definitive diagnosis while liquid biopsy improves access to molecular information and monitoring.
By application
By application, Lung Cancer held a strong position in 2025 because it requires both tissue diagnosis and molecular profiling for therapy selection. Breast Cancer and Prostate Cancer also represent major application areas due to large patient pools, biopsy-guided diagnosis and biomarker testing. Colorectal Cancer, Stomach Cancer and Liver Cancer are gaining importance as screening, endoscopy, imaging-guided biopsy and molecular testing expand across larger urban care networks. Cervical Cancer remains relevant because Latin America continues to focus on earlier diagnosis and pathology confirmation. Kidney Cancer, Bladder Cancer, Esophagus Cancer and Other Cancers support additional demand for biopsy instruments, kits, consumables and services. Growth across applications will depend on diagnostic access, oncology guidelines and reimbursement pathways.
By end user
By end user, Hospitals held the strongest position in 2025 because they manage complex cancer diagnosis, biopsy procedures, pathology services and oncology treatment pathways. Hospitals also support image-guided tissue biopsies, surgical biopsies, molecular testing referrals and multidisciplinary tumor boards. Diagnostic Centres represent a major growth segment because private laboratories and specialized diagnostic networks are expanding access to histopathology, cytology and molecular oncology testing. Research Institutes support demand through translational oncology, clinical trials, biomarker discovery and validation of tissue and liquid biopsy methods. Growth across end users will favor organizations that can combine specimen quality, pathology expertise, molecular testing and faster turnaround times.
Key market drivers
Rising cancer burden and diagnostic demand
Rising cancer burden and diagnostic demand represent a major growth driver for the Latin America Cancer Biopsy Market. Higher cancer detection volumes increase demand for biopsy instruments, kits, consumables and services across hospitals and Diagnostic Centres. Biopsy remains essential for confirming malignancy, identifying cancer type and guiding treatment selection. Demand is strongest across Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and Cervical Cancer because these indications require reliable diagnosis and follow-up testing. Expanding oncology infrastructure in major Latin American countries is also improving access to pathology and molecular testing. This driver will remain central through 2032 as health systems focus on earlier cancer diagnosis and more accurate treatment planning.
Precision oncology and molecular profiling
Precision oncology and molecular profiling support market growth as treatment decisions increasingly depend on tumor genetics, biomarkers and actionable mutations. Tissue and liquid biopsy samples are critical for next-generation sequencing, companion diagnostics and targeted therapy selection. Hospitals and Diagnostic Centres are expanding their laboratory capabilities to support biomarker testing for lung, breast, colorectal, prostate and other cancers. Molecular profiling also increases demand for sample preparation kits, reagents, sequencing consumables and specialized laboratory services. The shift toward precision medicine makes biopsy quality and testing accuracy more important for clinical decision-making. This driver will support strong long-term demand for both tissue and liquid biopsy workflows.
Liquid biopsy adoption
Liquid biopsy adoption is strengthening the market because blood-based testing can support genomic profiling, treatment monitoring and detection of resistance mechanisms with less invasive sampling. It is particularly useful when tumor tissue is difficult to collect, insufficient or unsafe to access. Liquid biopsy can also help patients who need repeated testing during therapy. Adoption in Latin America remains at an early-to-expanding stage because cost, reimbursement, awareness and laboratory infrastructure vary by country. However, private health care networks, oncology centers and research institutes are increasingly exploring liquid biopsy for advanced cancer management. This driver will create high-value opportunities for molecular diagnostics companies and service providers.
Expansion of private diagnostics and specialty laboratories
Expansion of private diagnostics and specialty laboratories is improving access to cancer biopsy testing across Latin America. Private diagnostic networks are investing in histopathology, immunohistochemistry, molecular testing and sample logistics to serve hospitals, oncologists and patients. These networks can improve turnaround times, standardize workflows and increase access to advanced testing in large cities. Specialty laboratories also help address gaps in public health systems where equipment, staffing or funding may be limited. Diagnostic Centres are expected to gain share as physicians refer more patients for tissue analysis, liquid biopsy and biomarker testing. This driver will support demand for consumables, kits, sequencing platforms and outsourced services.
Key Trends and Opportunities
Liquid biopsy and noninvasive testing expand
Liquid biopsy and noninvasive testing are becoming major opportunities because they can reduce dependence on invasive tissue collection in selected cases. Blood-based cancer testing supports therapy selection, treatment monitoring and resistance mutation detection. This is valuable in advanced lung cancer, colorectal cancer, breast cancer and prostate cancer where repeated testing may be required. Liquid biopsy also creates opportunities for companies offering sample collection tubes, extraction kits, sequencing services, bioinformatics and companion diagnostics. Adoption will grow first in private hospitals, oncology centers and specialty laboratories. Broader expansion will depend on cost reduction, clinical validation and reimbursement support.
Companion diagnostics gain clinical relevance
Companion diagnostics are gaining clinical relevance as oncology treatment becomes more biomarker-driven. Drug approvals increasingly require tests that identify patients eligible for targeted therapies or immunotherapy combinations. This trend increases demand for biopsy-based molecular testing across major cancer indications. Hospitals and Diagnostic Centres need validated workflows, standardized kits and high-quality instruments to support clinical decisions. Pharmaceutical companies may also partner with diagnostic firms to improve test access in Latin America. The opportunity is strongest in Lung Cancer, Breast Cancer, Colorectal Cancer and Prostate Cancer, where biomarker-defined treatment pathways are expanding.
Outsourced biopsy testing services grow
Outsourced biopsy testing services are growing as hospitals and smaller laboratories refer complex molecular tests to specialized providers. This model helps health care systems access advanced testing without immediately investing in expensive instruments, sequencing platforms and bioinformatics teams. Outsourced services also support clinical trials, research institutes and pharmaceutical partnerships. Service providers can differentiate through faster turnaround, quality accreditation, broader test menus and strong sample logistics. Demand will increase as oncology care requires more biomarker data and treatment monitoring. Companies that connect local collection networks with regional or global testing infrastructure will gain stronger market access.
Key Market Challenges
Limited reimbursement and affordability constraints
Limited reimbursement and affordability constraints remain key challenges for the Latin America Cancer Biopsy Market. Advanced biopsy tests, molecular panels and liquid biopsy assays can be expensive for patients and health systems. Public reimbursement coverage varies widely across countries and may not fully support newer genomic tests. Private insurance can improve access, but coverage remains uneven. Cost sensitivity can delay adoption of liquid biopsy and broad sequencing panels. Suppliers and laboratories must demonstrate clinical value, cost-effectiveness and treatment relevance to improve adoption.
Infrastructure gaps and laboratory capacity limits
Infrastructure gaps and laboratory capacity limits can slow market expansion. Many areas still face shortages of trained pathologists, molecular laboratory specialists, sequencing infrastructure and quality-controlled sample logistics. Rural and underserved regions may rely on centralized testing hubs, which can increase turnaround time and affect sample quality. Liquid biopsy and companion diagnostics require validated workflows, data interpretation and quality assurance. Smaller laboratories may struggle to invest in advanced instruments and bioinformatics. Capacity-building, training and public-private partnerships will be important to address this challenge.
Sample quality and workflow standardization
Sample quality and workflow standardization create challenges across tissue and liquid biopsy testing. Poor specimen handling, delayed fixation, insufficient tumor content and inconsistent processing can affect diagnostic accuracy. Liquid biopsy testing also requires careful blood collection, stabilization, storage and transport to preserve circulating tumor DNA or cells. Variability across hospitals, laboratories and countries can limit confidence in results. Standardized kits, training, accreditation and quality control programs are essential for reliable testing. Companies that support end-to-end workflows will have an advantage.
Regional Analysis
Brazil
Brazil represents the largest opportunity within the Latin America Cancer Biopsy Market due to its large population, advanced private health care sector and growing oncology infrastructure. Demand is supported by hospitals, cancer centers, diagnostic laboratories and research institutes that use tissue and liquid biopsy for diagnosis, staging and treatment selection. Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer and Cervical Cancer create strong procedural demand. Private laboratories are expanding molecular oncology testing and sample logistics capabilities. Brazil will remain a priority market for biopsy instruments, consumables, kits and advanced testing services through 2032.
Mexico
Mexico represents a major market supported by private hospital networks, diagnostic laboratories and improving oncology care access. Biopsy demand is strongest across Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer and Cervical Cancer. Hospitals remain central for complex tissue biopsy procedures, while Diagnostic Centres support histopathology, cytology and molecular testing. Liquid biopsy adoption is growing gradually in advanced oncology centers and private laboratories. Mexico’s market expansion will depend on reimbursement, laboratory quality, physician awareness and cross-border partnerships. It is expected to remain one of the key Latin American growth markets.
Argentina
Argentina supports steady demand for cancer biopsy products and services through hospitals, private laboratories, cancer centers and academic research institutions. Tissue Biopsies remain dominant, while Liquid Biopsies are gaining attention for precision oncology and advanced cancer monitoring. Demand is supported by colorectal, breast, lung and prostate cancer testing needs. Economic volatility and reimbursement limitations can affect access to high-cost molecular testing. However, clinical expertise and research capabilities support adoption of advanced diagnostic methods in major urban centers. Argentina will remain an important market for specialized biopsy services and molecular oncology testing.
Colombia
Colombia is an emerging growth market supported by expanding private health care, oncology treatment networks and diagnostic laboratory investment. Hospitals and Diagnostic Centres are improving access to tissue biopsy, immunohistochemistry and molecular testing. Demand is supported by Breast Cancer, Lung Cancer, Stomach Cancer, Colorectal Cancer and Cervical Cancer diagnosis. Urban centers have stronger access to advanced testing, while rural areas still face diagnostic capacity gaps. Liquid biopsy adoption remains selective but offers long-term growth potential. Colombia will benefit from better sample logistics, laboratory standardization and partnerships with global diagnostics firms.
Chile
Chile represents a smaller but quality-focused market with relatively strong health care infrastructure and growing demand for advanced diagnostics. Hospitals and private laboratories support biopsy procedures, pathology services and molecular testing for major cancer indications. Tissue Biopsies remain central, while Liquid Biopsies are expected to gain traction in specialized oncology settings. The market benefits from stronger clinical awareness and a growing emphasis on precision medicine. High test cost remains a constraint for broad adoption. Chile will remain attractive for premium biopsy technologies, services and research-linked testing.
Rest of Latin America
Rest of Latin America includes markets with varied diagnostic capacity, reimbursement structures and oncology infrastructure. Demand is supported by rising cancer diagnosis, public health initiatives, private diagnostic networks and gradual improvement in pathology services. Tissue Biopsies remain the dominant type because they are essential for diagnosis and widely accepted in clinical practice. Liquid Biopsies will expand more gradually, led by private health care providers and advanced oncology centers. Market growth will depend on affordability, laboratory infrastructure, training and sample logistics. Suppliers that offer scalable kits, consumables and service partnerships can expand access in these markets.
Report Attribute Details
| Report Attribute |
Details |
| Historical Period |
2021–2024 |
| Base Year |
2025 |
| Forecast Period |
2025–2032 |
| Market Size in 2021 |
USD 6,236.16 MN |
| Market Size in 2025 |
USD 9,108.79 MN |
| Market Size in 2032 |
USD 18,855.52 MN |
| CAGR |
9.20% |
| Segments Covered |
Product, Type, Application, End User and Geography |
| Key Companies Covered |
QIAGEN, Illumina, Inc., ANGLE plc, BD, Biodesix, Lucence Health Inc., Myriad Genetics, Inc., Hologic, Inc., Oncimmune Holdings PLC, F. Hoffmann-La Roche Ltd., Guardant Health Inc. and Epigenomics AG |
Latin America Cancer Biopsy Market Segmentations
By Product
- Instrument
- Kits
- Consumables
- Services
By Type
- Tissue Biopsies
- Liquid Biopsies
By Application
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Esophagus Cancer
- Cervical Cancer
- Kidney Cancer
- Bladder Cancer
- Other Cancers
By End User
- Hospitals
- Diagnostic Centres
- Research Institutes
Key Players
- QIAGEN
- Illumina, Inc.
- ANGLE plc
- BD
- Biodesix
- Lucence Health Inc.
- Myriad Genetics, Inc.
- Hologic, Inc.
- Oncimmune Holdings PLC
- F. Hoffmann-La Roche Ltd.
- Guardant Health Inc.
- Epigenomics AG
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Recent Developments
- In February 2025, Hologic obtained CE Mark for Affirm Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with lesion targeting to support breast biopsy workflows.
- In May 2025, Guardant Health introduced new Smart Liquid Biopsy applications for Guardant360 Liquid, expanding the company’s blood-based approach to cancer molecular profiling.
- In June 2025, QIAGEN expanded its oncology diagnostics portfolio through strategic partnerships focused on minimal residual disease testing in clinical trials and companion diagnostic development.
- In April 2026, Roche’s Foundation Medicine moved to strengthen its monitoring portfolio with SAGA Diagnostics’ tumor-informed molecular residual disease platform through Roche’s definitive merger agreement to acquire SAGA.
Report Coverage
The research report offers an in-depth analysis based on product, type, application, end user and geography. It details leading market players, providing an overview of their business positioning, biopsy product portfolios, molecular diagnostic capabilities, laboratory services and strategic relevance in the Latin America Cancer Biopsy Market. The report includes insights into the competitive environment, market trends, growth drivers, restraints and opportunities. It also examines cancer diagnosis volume, tissue biopsy use, liquid biopsy adoption, molecular profiling, companion diagnostics and expansion of private diagnostic networks as major factors shaping market development. The report assesses the impact of affordability, reimbursement, laboratory infrastructure, sample quality and workflow standardization on market growth. It provides strategic recommendations for diagnostic companies, hospitals, Diagnostic Centres, research institutes, laboratory service providers, investors and new entrants seeking to navigate Latin America’s cancer biopsy ecosystem.
Future Outlook
- Demand for cancer biopsy products will continue to rise as Latin American health systems expand cancer diagnosis and precision oncology capabilities.
- Consumables will remain a major product category due to recurring use across tissue processing, sample preparation and molecular testing workflows.
- Kits will gain demand as laboratories standardize biopsy workflows and adopt molecular oncology testing.
- Tissue Biopsies will remain the leading type because they are essential for diagnosis, histology, grading and biomarker confirmation.
- Liquid Biopsies will grow quickly as blood-based genomic profiling and treatment monitoring gain clinical acceptance.
- Lung Cancer, Breast Cancer, Colorectal Cancer and Prostate Cancer will remain key application areas for biopsy testing.
- Hospitals will remain the leading end users because complex biopsy procedures and oncology treatment pathways are concentrated in hospital networks.
- Diagnostic Centres will gain share as private laboratories expand histopathology, cytology and molecular testing services.
- Brazil and Mexico will remain major demand centers, while Colombia and Chile will support steady growth in advanced diagnostic adoption.
- Competition will increase as global diagnostics companies compete on test accuracy, sample workflow, laboratory partnerships, service reach and affordability.
